Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

BACKGROUND: Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and drive therapeutic options. The SAUL trial investigated the safety and efficacy of atezolizumab in a real-world setting on 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., Sternberg, C.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134706/
https://www.ncbi.nlm.nih.gov/pubmed/33984678
http://dx.doi.org/10.1016/j.esmoop.2021.100118

Ejemplares similares

Ejemplares similares